Crispr Therapeutics named a top pick for 2019 at Piper Jaffray. Piper Jaffray analyst Edward names Crispr Therapeutics a top pick for 2019 and reiterates an Overweight rating on the shares with a $75 price target. The stock closed the trading day up $1.30 to $29.87. Crispr is developing “revolutionary” CRISPR/Cas-9 technology as a new therapeutic modality with broad ranging applicability, Tenthoff tells investors in a research note. The Phase I/II studies of CTX-001 in transfusion-dependent beta thalassemia and sickle cell disease will report first-in-man data this year potentially curing patients of disease, adds the analyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.